Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001075691 | SCV001241319 | likely pathogenic | Retinal dystrophy | 2019-04-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002554769 | SCV003239999 | pathogenic | PRPH2-related disorder | 2022-09-29 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PRPH2 protein in which other variant(s) (p.Val332Glu) have been determined to be pathogenic (PMID: 30718709, 32531846; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 867132). This variant has not been reported in the literature in individuals affected with PRPH2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change results in a frameshift in the PRPH2 gene (p.Ser322Cysfs*69). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 25 amino acid(s) of the PRPH2 protein and extend the protein by 43 additional amino acid residues. |